ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
Completed · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ATN-161 together with carboplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of ATN-161 when given together with carboplatin and to see how well they work in treating patients with recurrent malignant glioma.
Key facts
- Study ID
- NCT00352313
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 82
- Starts
- 2006-05-01
- Expected to finish
- 2008-01-01
- Last updated by the study team
- 2012-05-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.